| Literature DB >> 30232095 |
Thomas Günther1, Giovanni Tulipano1, Pascal Dournaud1, Corinne Bousquet1, Zsolt Csaba1, Hans-Jürgen Kreienkamp1, Amelie Lupp1, Márta Korbonits1, Justo P Castaño1, Hans-Jürgen Wester1, Michael Culler1, Shlomo Melmed1, Stefan Schulz2.
Abstract
Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein-coupled receptors (GPCRs) called somatostatin receptor (SST)1-5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST2 and SST5 receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30232095 PMCID: PMC6148080 DOI: 10.1124/pr.117.015388
Source DB: PubMed Journal: Pharmacol Rev ISSN: 0031-6997 Impact factor: 25.468